News tagged with lenalidomide
New multiple myeloma treatment guidelines personalize therapy for patients
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to ...
Cancer
Apr 01, 2013 |
not rated yet |
0
New drug improves survival in multiple myeloma relapse
Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with ...
Cancer
Jan 24, 2013 |
not rated yet |
0
Lenalidomide offers an effective alternative treatment for cutaneus lupus erythematosus
Although rare there are several treatments available for cutaneus lupus erythematosus (CLE). However other options are needed for people who do not respond to medication or relapse. A new study into the thalidomide derivative ...
Cancer
Dec 07, 2012 |
not rated yet |
0
|
Researchers harness the immune system to improve stem cell transplant outcomes
A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant ...
Immunology
Oct 01, 2012 |
5 / 5 (1) |
0
|
Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid, following a stem cell transplant, according to a study co-authored by a physician with the ...
Cancer
May 16, 2012 |
not rated yet |
0
Study shows benefit of new maintenance therapy for multiple myeloma
Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called ...
Cancer
May 11, 2012 |
5 / 5 (1) |
0
|
New drug shows promise for myeloma patients
(HealthDay) -- Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem ...
Cancer
May 09, 2012 |
5 / 5 (1) |
0
|
Chemo combination promising for multiple myeloma
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response ...
Cancer
May 02, 2012 |
not rated yet |
0
How patients will respond to immunomodulator therapy for multiple myeloma
Research on the same protein that was a primary mediator of the birth defects caused by thalidomide now holds hope in the battle against multiple myeloma, says the study's senior investigator, Keith Stewart, M.B., Ch.B. of ...
Cancer
Dec 11, 2011 |
5 / 5 (1) |
0
Drug combination highly effective for newly diagnosed myeloma patients, study finds
(Medical Xpress) -- A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej ...
Cancer
Dec 08, 2011 |
not rated yet |
0
Study urges caution with lenalidomide dosage
An early phase multiple myeloma trial has unexpectedly revealed that the drug lenalidomide interacts with another protein in cells that affect its dose level in the body, say researchers at the Ohio State University Comprehensive ...
Medications
Aug 08, 2011 |
not rated yet |
0
|
Lenalidomide
Lenalidomide ( /lɛnəˈlɪdɵmaɪd/), initially known as CC-5013 and marketed as Revlimid by Celgene, is a derivative of thalidomide introduced in 2004.
It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide and bortezomib are considered therapeutic breakthroughs in the treatment of myeloma, which generally carries a poor prognosis.
For more information about Lenalidomide, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
